Beta Bionics Q3 Sales Up 30% but Losses Widen; 3D Intelligence 510(k) Withdrawn
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Q3 net sales came in at $35.5 million, up 30% from $27.3 million a year ago, with the pharmacy benefit channel more than doubling to $13.6 million. Gross margin improved to 57.3% from 55.5%. The problem is the bottom line: the quarterly loss was $24.4 million, or 52 cents a share, operating loss widened to $26.6 million (negative 75% of sales) from $17.0 million, and adjusted EBITDA fell to negative $18.9 million from negative $12.2 million as sales and marketing spend jumped to $25.1 million. Management narrowed full-year revenue guidance to $124-126 million from $121-126 million, but flagged up to $8.5 million of potential Q4 revenue deferral as new iLet users wait for the Mint patch pump launch in Q1 2027, and expects Mint to recapture any revenue lost from the fourth quarter of 2026 during fiscal 2027. Separately, the company withdrew its 510(k) for the 3D Intelligence algorithm and now plans a revised submission in mid-Q4 2026, pushing U.S. commercialization of iLet 3D and Mint 3D to the first half of 2027. Cash and investments stood at $373.6 million after the September offering, so funding is not the near-term issue — the widening loss rate and the regulatory delay are. This follows the September FDA clearance of Mint and the $172.5 million offering close, and comes after the October 6 safety disclosure that sent shares down 37%.
Updates
· SEC 8-K — Beta Bionics' FY2026 revenue guidance is now approximately $124 million to $126 million, and the revised 3D Intelligence 510(k) is planned for mid-Q4 2026.
At the time of this announcement, BBNX was trading at $21.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.80 to $32.71. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.